SCHEMBL3373193

SCHEMBL3373193

CCOC(Cc1ccc(OCc2csc(-c3ccccc3Cl)n2)cc1C)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 11/20 0.49
PPARA Q07869 10/20 0.41
PPARD Q03181 2/20 0.41
FFAR2 O15552 1/20 0.39
ALDH1A1 P00352 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
SHMT1 P34896 1/20 0.39
S1PR1 P21453 2/20 0.38
S1PR5 Q9H228 2/20 0.38
PDGFRA P16234 1/20 0.38
ROCK1 Q13464 1/20 0.38
NPC1 O15118 1/20 0.38
LMNA P02545 1/20 0.38
CASP3 P42574 1/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 1/20 0.38
SENP8 Q96LD8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3371064 0.93 PPARG (0.47) PPARGPPARAFFAR2ALDH1A1TDP1
SCHEMBL3372464 0.89 PPARA (0.47) PPARGPPARAPPARDALDH1A1L3MBTL1
SCHEMBL3369875 0.87 PPARA (0.48) PPARGPPARAPPARDLMNA
SCHEMBL3373870 0.87 PPARA (0.48) PPARGPPARAPPARDLMNA
SCHEMBL3372523 0.86 PPARA (0.51) PPARGPPARAPPARDALDH1A1L3MBTL1
SCHEMBL3401607 0.86 PPARA (0.51) PPARGPPARAPPARDALDH1A1L3MBTL1
SCHEMBL3369128 0.85 FFAR2 (0.53) PPARGPPARAPPARDFFAR2
SCHEMBL3369621 0.85 EIF4E (0.41) PPARGPPARAPPARDALDH1A1LMNA
SCHEMBL6527178 0.85 EIF4E (0.41) PPARGPPARAPPARDALDH1A1LMNA
SCHEMBL3368818 0.84 PPARA (0.42) PPARGPPARAPPARDALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537091-B1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS HOFFMANN LA ROCHE (CH) 2010-10-06 EP disclosed
EP-1537091-A1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2005-06-08 EP disclosed
US-6809110-B2 NONINSULIN DEPENDENT DIABETES; SUCH AS 2-ETHOXY-3-(4-(2-(5-METHYL-2-PHENYL-THIAZOL-4-YL)-ETHOXY)-BENZO(B)THIOPHEN-7-YL)-PROPIONIC ACID HOFFMANN-LA ROCHE INC. 2004-10-26 US disclosed
US-20040110807-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2004-06-10 US disclosed
WO-2004020420-A1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2004-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110807-A1 Thiazole derivatives SLC5A1, GPR119, INSR PPARG 181/4885PPARA 287/4885PPARD 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.